# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Theodore Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI012-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amos Kettering, MD
- Calendar frame: modern shifted

## Reason for visit

Primary care visit for frequent wheeze, night cough, and breathlessness during training. **S**

## Historical basis

- Theodore Roosevelt was born at 28 East 20th Street, New York City, on October 27, 1858. **D**
- In his autobiography Roosevelt wrote that he was a sickly, delicate boy who suffered much from asthma and frequently had to be taken away on trips to find a place where he could breathe; he remembered sitting up in bed gasping at night as a very small child. **D**
- When he was nearly fourteen, during an attack of asthma, he was sent alone to Moosehead Lake; after two other boys on the stage-coach easily overpowered him, he began boxing lessons and a long program of physical training, with his father's approval. **D**
- Roosevelt wrote that he was very near-sighted as a boy without knowing it, and that at about thirteen, after he could not read a distant billboard, he got his first pair of spectacles. **D**
- A 2015 review of the historical record in the Journal of Allergy and Clinical Immunology: In Practice concluded that his respiratory problems began in early childhood, that the record gives strong evidence for poorly controlled persistent asthma, that the asthma became relatively quiet in adolescence when his exercise program began at about 12, and that he continued to have serious exacerbations in adolescence and adulthood; it found little if any support for the claim that his asthma was psychosomatic. **R**
- Roosevelt received his Bachelor of Arts degree from Harvard in June 1880 and was elected to the New York State Assembly in 1881. **D**
- His father, Theodore Roosevelt Sr., died in 1878 shortly after being diagnosed with stomach cancer. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Wheeze, night cough, and breathlessness are limiting his training and his long days at work. **S**
- Would rather control his asthma with exercise than with daily medicine. **S**

## Strengths and supports

- Supports: close friends, a boxing coach, and colleagues at work **S**

## Medications and allergies

- Albuterol 90 mcg/actuation inhaler, two inhalations as needed for wheeze (bought after an urgent care visit; used most days before intake) **S**
- Budesonide-formoterol 160/4.5 mcg inhaler, two inhalations twice daily for maintenance **S**
- Budesonide-formoterol 160/4.5 mcg inhaler, one inhalation as needed for symptoms and before exercise; no more than 12 inhalations a day in total **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1860s: Severe childhood asthma, with night attacks in which he sat up in bed gasping, and trips away from home to find a place where he could breathe **D** (CLM-0002)
- 1872: Near-sightedness discovered at about thirteen; first spectacles **D** (CLM-0004)
- 1872: Asthma attack at nearly fourteen, after which he was sent to Moosehead Lake and began boxing and a program of physical training **D** (CLM-0003)

## Procedures and immunizations

- 2026-03-09 to 2026-03-09: Spirometry before and after albuterol 400 mcg: FEV1 3.20 L (72 percent predicted), FEV1/FVC 0.67, FEV1 rising to 3.74 L after bronchodilator **S**
- 2026-03-09 to 2026-03-09: Written asthma action plan with symptom and peak-flow zones; peak flow meter issued **S**
- 2025-10-14: Influenza vaccine, 2025-2026 season **S**
- 2019-08-12: Tdap vaccine **S**
- 2014-04-07: HPV 9-valent vaccine, two-dose series completed **S**

## Family history

- father: Died in 1878, shortly after a diagnosis of stomach cancer **D** (CLM-0007)

## Measurements

FEV1 before bronchodilator: 3.2 L (low); FEV1 percent predicted: 72% (low); FVC: 4.8 L; FEV1/FVC ratio: 0.67 (low); FEV1 after bronchodilator: 3.74 L; Asthma Control Test: 13; PHQ-2: 0. All results are synthetic.

BP 118/72 mmHg; pulse 84 bpm; respirations 18/min; temperature 36.8 °C; oxygen saturation 96% on room air; weight 72 kg; BMI 23.5 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, energetic, and talkative; asks detailed questions about every treatment; Mood good; PHQ-2 negative. Functional status: At intake, breathlessness ends his boxing rounds early and stops him rowing hard; night cough wakes him about twice a week; Back to full boxing, rowing, and hiking without limiting symptoms by the three-month review. Physical examination is intentionally limited. **S**

## Assessment

1. Moderate persistent asthma, uncontrolled at intake, with reversible airflow obstruction on spirometry; synthetic modern diagnosis linked to his documented lifelong asthma; status draft. **S**
2. Myopia, both eyes, corrected with glasses since boyhood; status draft. **S**

## Plan

- Stop reliever-only albuterol and start budesonide-formoterol maintenance-and-reliever therapy at Step 4 (two inhalations twice daily plus one as needed, up to 12 a day), with a spacer and inhaler-technique teaching. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Written asthma action plan with symptom and peak-flow zones (green 80 percent or more of personal best, yellow 50 to 79 percent, red below 50 percent), reviewed at every visit and after every exacerbation. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) **S**
- Pulmonology referral to confirm the diagnosis, assess type 2 inflammation, and advise on exercise-induced symptoms, allergen measures, and treatment step. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Asthma Control Test, inhaler technique, adherence, reliever use, triggers, and exacerbation history at every visit; review one to three months after starting controller therapy, then every three to twelve months, and within one week of any exacerbation; spirometry at diagnosis, three to six months after stabilization, then every one to two years. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) **S**
- Explain that exercise improves fitness but does not treat airway inflammation; take one reliever inhalation before boxing or rowing; use dust-mite-impermeable bedding covers once sensitization is shown. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Yearly influenza vaccine, pneumococcal vaccination for chronic lung disease, and COVID-19 vaccination by CDC guidance. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026); Summary of Risk-based Pneumococcal Vaccination Recommendations (2025) **S**

## Guideline basis

- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026), Aether Forge
- Summary of Risk-based Pneumococcal Vaccination Recommendations (2025), Centers for Disease Control and Prevention
